-
Settlement Reached in New Hampshire Opioid Case Against Johnson & Johnson
New Hampshire has reached a settlement with Johnson & Johnson in the state’s opioid case against the pharmaceutical company, four years after an initial complaint was filed. In a news release from Attorney General John Formella’s office, authorities say New Hampshire has reached a $40.5 million settlement with J&J subsidiary Janssen Pharmaceuticals. $31.5 million of that money is set...
-
FDA Restricts Johnson & Johnson's COVID-19 Vaccine
The Food and Drug Administration strictly limited who can receive Johnson & Johnson’s COVID-19 vaccine on Thursday due to the ongoing risk of rare but serious blood clots
-
Next Decade Will Transform Health Care More Than Past Century: Johnson & Johnson CEO
Johnson & Johnson’s new CEO Joaquin Duato says in his first interview that AI in medicine will lead to innovations including real-time surgery decisions.
-
5 Things to Know Before the Stock Market Opens Wednesday
U.S. stock futures fell Wednesday, one day after the Dow and S&P 500 logged four-session winning streaks and the Nasdaq saw back-to-back gains.
-
Johnson & Johnson COVID-19 Vaccine Shows Promising Long-Term Durability
Evidence suggests the J&J shot might have an edge in durability over Pfizer’s and Moderna’s vaccines.
-
Vaccine Maker Stocks Rise as China Battles Worst Covid Outbreak Since 2020
Shares of Moderna, BioNTech, Pfizer, Johnson & Johnson and Novavax rose on Monday as China battles its worst Covid outbreak in two years.
-
Pfizer Planning to Submit Data on 4th Covid Shot Soon, While Working on Vaccine for All Variants
Pfizer CEO Albert Bourla appeared on CNBC exactly two years after Covid was declared a pandemic by the WHO on March 11, 2020.
-
Omicron BA.2 Subvariant Is More Contagious and Can Reinfect People, But Isn't More Severe, Studies Find
A pandemic-weary public wants to know two main things: Will BA.2 cause a second surge of cases, and will it put even more people in the hospital?
-
This ETF Is Designed to Help Fight Heart Disease While Making You Money. Here's How
It’s an ETF looking to make you money while saving lives.
-
Moderna, Pfizer Stocks Fall as Covid Omicron Wave Subsides in U.S.
Moderna plunged more than 12%, the biggest decline in the S&P 500 as of midafternoon Monday.
-
‘Inflation Narrative' Has Given Rise to These Specialty ETFs, Market Analyst Says
Commodity, dividend and risk-focused exchange-traded funds are gaining traction alongside concerns around inflation, ETF Action’s Mike Akins says.
-
Johnson & Johnson Plant Pauses Covid Vaccine Production, Report Says
The only Johnson & Johnson facility making usable batches of the company’s Covid vaccine has temporarily halted its production, The New York Times reported.
-
Moderna's Covid Vaccine for Teens Awaits OK as Regulators Review Heart Inflammation Risk
Moderna applied for emergency approval of its Covid vaccine for 12- to 17-year-olds in June, but the FDA said its review wouldn’t be completed before January.
-
Native American Tribes Reach $590 Million Opioid Settlement
Native American tribes have reached opioid settlements worth over a half-billion dollars with drugmaker Johnson & Johnson and three distributors
-
Hollywood Agencies Are Betting Big on TikTok Talent as They Seek to Woo Gen Z Audiences
Hollywood agencies are using TikTok to find new talent and harnessing the skills these content creators possess to bolster the careers of already established clients.
-
Cramer Says the Stock Market Is Being Dragged Down by 2021's Flurry of IPOs and SPAC Deals
“A stock market’s like any other market, if you get too much inventory, prices will plummet,” the “Mad Money” host said.
-
Johnson & Johnson More Bullish on Acquisitions in Volatile Market: CFO
Market volatility will lead cash-rich companies to be more opportunistic on mergers and acquisitions in 2022, including Johnson & Johnson, according to its CFO.
-
Stocks Making the Biggest Moves Midday: American Express, General Electric, IBM and More
These are the stocks posting the largest moves in midday trading.
-
Cramer Advises Investors to Stick With ‘Great American Companies' to Weather Market Swings
While many of those firms might look to be in a dismal state, CNBC’s Jim Cramer encouraged buyers to watch the big picture.
-
COVID Q&A: Top Boston Doctors Talk New Omicron Subvariant, Next Steps Post-Surge Peak
Top Boston doctors talk about next steps now that the omicron surge has peaked, the new omicron subvariant BA.2, variant-specific vaccines, natural immunity and masks in schools on NBC10 Boston’s weekly “COVID Q&A” series.